Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript
Operator: Good day ladies and gentlemen. Thank you for standing by and welcome to Akebia's Fourth Quarter 2022 Financial Results Conference Call.
Akebia Therapeutics Inc. (AKBA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 217,149 | $125,295 | +1% | 0% |
| 2. | 89,200 | $51,468 | +19% | 0% | |
| 3. | 19,000 | $10,963 | -42% | 0% | |
| 4. | Citadel Investment Group Ken Griffin | 13,397 | $7,730 | -96% | 0% |
| 5. | Renaissance Technologies Jim Simons | 2,886,227 | $1,665 | -5% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.43 | 5,800 | 29,731 | 2019-11-20 | Filing | ||
| $3.52 | 15,000 | 28,700 | 2019-11-20 | Filing | ||
| $3.58 | 27,000 | 37,000 | 2019-11-20 | Filing | ||
| $3.44 | 50,000 | 887,732 | 2019-11-20 | Filing | ||
| $3.41 | 50,000 | 63,700 | 2019-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.88 | 6,370 | 1,568,872 | 2023-03-01 | Filing | ||
| $0.88 | 47,239 | 1,575,242 | 2023-03-01 | Filing | ||
| $0.88 | 38,259 | 1,622,481 | 2023-03-01 | Filing | ||
| $0.88 | 1,088 | 287,530 | 2023-03-01 | Filing | ||
| $0.88 | 6,613 | 288,618 | 2023-03-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 15,090,119 | $8,706,999 | 10.01% | |
| 2. | 11,238,870 | $6,484,828 | 0% | |
| 3. | 2,922,545 | $1,686,310 | 0% | |
| 4. | 2,014,767 | $1,162,521 | 0% | |
| 5. | 1,020,032 | $588,558 | 0% |
News See All
5 Underperforming Stocks Targeted By Short Sellers
In this article we discuss top 5 underperforming stocks targeted by short sellers.
Is AKBA A Good Stock To Buy Now?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Hedge Funds Have Never Been This Bullish On Akebia Therapeutics Inc (AKBA)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Were Hedge Funds Right About Warming Up To Akebia Therapeutics Inc (AKBA)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Are Buying Akebia Therapeutics Inc (AKBA)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.
Did Hedge Funds Drop The Ball On Akebia Therapeutics Inc (AKBA) ?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Akebia Therapeutics Inc (AKBA) Is Burning These Hedge Funds
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with...
Hedge Funds Are Dumping Akebia Therapeutics Inc (AKBA)
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because...
Here's What Hedge Funds Think About Akebia Therapeutics Inc (AKBA)
The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates.
Billionaire Hedge Funds
